Ajinomoto Co., Ltd.

Ea Pharma Co., Ltd.

Sayaka Asari

Keita Fukui

Benjamin Mijts

Miku Toyazaki

Christine Roche

Tetsuo Yano

Yuzuru Eto

Masayuki Sugiki

Naoyuki Fukuchi

Toshihiro Hatanaka

Naohiro Miyamura

Hiroaki Nagasaki

Reiko Yasuda

Itsuya Tanabe

Toru Okamatsu

Yayoi Kawato

Yukie Seki

Peter Kelly

Takashi Yamamoto

Tamotsu Suzuki

Hideki Matsumoto

Koji Ohsumi

Tatsuya Okuzumi

Munetaka Tokumasu

Akira Chiba

Shingo Makino

Satoshi Iwayama

Shinichi Fujita

Koichi Fujita

Masataka Shoji

Misato Noguchi

Yasuaki Takakura

Kaori Kobayashi

Youji Yamada

Masaki Hashimoto

Keiko Noguchi

Keiko Danjo

Seiji Shiraishi

Chiori Ijichi

Takuto Ono

Matthew Davis

Yuka Kataba

Naoko Oomuta

Yuko Iida

Rekha Murali

A method for producing an objective substance such as vanillin and vanillic acid is provided. An objective substance is produced from a carbon source or a precursor of the objective substance by using a microorganism that is able to produce the objective substance, which microorganism has been modified so that the activity of an enzyme involved in SAM cycle (SAM cycle enzyme) is increased.

Method for producing objective substance

A method for producing an objective substance such as vanillin and vanillic acid is provided. An objective substance is produced from a carbon source or a precursor of the objective substance by using a microorganism having an objective substance-producing ability, which microorganism has been modified so that the activity of S-adenosyl-L-homocysteine hydrolase is increased.

A method for producing an objective substance such as vanillin and vanillic acid is provided. An objective substance is produced from a carbon source or a precursor of the objective substance by using a microorganism having an objective substance-producing ability, which microorganism has been modified so that the activity of enolase is reduced.

A method for producing an objective substance such as vanillin and vanillic acid is provided. An objective substance is produced from a carbon source or a precursor of the objective substance by using a microorganism having an objective substance-producing ability, which microorganism has been modified so as to have a specific feature, such as a reduced activity of AICAR formyltransferase/IMP cyclohydrolase, an increased activity of 3-PGDH, and/or a reduced activity of L-serine deaminase.

A method for producing benzaldehyde is provided. Benzaldehyde is produced from L-phenylalanine or a carbon source by using microorganism(s) having amino acid deaminase, 4-hydroxymandelate synthase, (S)-mandelate dehydrogenase, and benzoylformate decarboxylase.

Method for producing benzaldehyde

The present invention aims to provide a novel compound having a TRPA1 antagonist activity, and a medicament containing the compound. Moreover, the present invention aims to provide a TRPA1 antagonist and a medicament useful for the prophylaxis or treatment of diseases involving TRPA1. A medicament containing a compound represented by the formula (I): wherein each symbol is as defined in the DESCRIPTION, or a pharmaceutically acceptable salt thereof, and the like.

Heterocyclic amide derivative and pharmaceutical product containing same

By searching various kinds of compounds having CaSR agonistic activity, the present invention provides CaSR agonistic agents, pharmaceutical compositions, preventive or therapeutic agents for diarrhea and kokumi-imparting agents each of which comprise the compound. More specifically, the present invention provides CaSR agonistic agents, pharmaceutical compositions, preventive or therapeutic agents for diarrhea and kokumi-imparting agents each of which comprise a glutamic acid derivative having CaSR agonistic activity or pharmaceutically acceptable salts thereof.

CaSR agonists

The present invention provides a piperidine derivative represented by the following formula or analogs thereto, which are used for agents for treating or preventing various diseases related to 5-HT7. 

Piperidine derivative

Azole compounds represented by formula I: wherein ring A is isoxazole and the like, R1 is a substituted or unsubstituted aryl group and the like, R2 is a hydrogen atom and the like, and R3 is a substituted or unsubstituted alkyl group and the like, and pharmaceutically acceptable salts thereof inhibit the physiological activity of lysophosphatidic acid (LPA), and are useful as for the prophylaxis or treatment of diseases in which inhibition of the physiological activity of LPA is useful for the prophylaxis or treatment thereof, such as diseases involving the LPA receptor.

Azole compound

Growing community of inventors

Kawasaki, Japan

Sayaka Asari